MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Personal Cancer Immunotherapy
    • The Clean Super Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Personal Cancer Immunotherapy
    • The Clean Super Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  

AIVITA Biomedical’s Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science

IRVINE, Calif. –  October 9, 2020 – AIVITA Biomedical announced the publication of the peer-reviewed manuscript, “Retina organoid transplants…

AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management

IRVINE, Calif. –  August 3, 2020 – AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the…

AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research

IRVINE, Calif. – July 1, 2020 – AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the…

AIVITA Biomedical Presents Updates from Ongoing Ovarian Cancer and Glioblastoma Clinical Studies at 2020 AACR Virtual Annual Meeting

IRVINE, Calif. – April 27, 2020 – AIVITA Biomedical, Inc., a biotechnology company specializing in innovative cell therapy applications,…

AIVITA Biomedical Publishes Study Comparing Immune Responses and Associated Survivals Induced by Dendritic and Tumor Cell Vaccines

IRVINE, Calif. – April 23, 2020 – AIVITA Biomedical, Inc., a biotechnology company specializing in innovative cell therapy applications,…

AIVITA Biomedical Provides Update of Ongoing Phase 2 Glioblastoma Trial from Year-End Survival Analysis

IRVINE, Calif. – April 8, 2020 – AIVITA Biomedical, Inc., a biotechnology company specializing in innovative cell therapy applications,…

AIVITA Biomedical Raises $12.5 Million in Series B-2 Financing Round and Announces New Board of Directors Appointee

IRVINE, Calif. – February 25, 2020 – AIVITA Biomedical, Inc., a biotechnology company (the “Company”) specializing in innovative stem…

AIVITA Biomedical to Present at 2020 BIO CEO & Investor Conference

IRVINE, Calif. – February 10, 2020 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications,…

AIVITA Biomedical Completes Patient Recruitment in Phase 2 GBM Trial

IRVINE, Calif. – February 4, 2020 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications,…

AIVITA Biomedical to Present at Biotech Showcase 2020

IRVINE, Calif. – January 14, 2020 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications,…

  • Previous
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target infectious diseases and tumor-initiating cells — the seed of all cancers — using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Publishes a Universal Dendritic Cell Cancer Vaccine Platform
  • AIVITA Biomedical Strengthens Board of Directors with Appointment of Global Health and Vaccine Readiness Leader Larry Brilliant
  • AIVITA Biomedical Nominated for 2026 Prix Galien USA Award
  • AIVITA Biomedical Licenses Novel Skincare Formulations to Global Skincare Retailer LevEllis
  • AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2023 | AIVITA Biomedical, Inc.